论文部分内容阅读
Checkmate 032:Nivolumab(N)alone or in combination with ipilimumab(I)for thetreatment of recurrent sm
【作 者】
：
【机 构】
：
Moffitt Cancer Center,Tampa,FL '12 de Octubre'
【出 处】
：
2016年临床肿瘤学新进展学术研讨会
【发表日期】
：
2016年5期
其他文献
Phase Ⅲ randomized controlled study of daratumumab,bortezomib,and dexamethasone(DVd)versus bortezomi
会议
Pembrolizumab versus ipilimumab for advanced melanoma:Final overall survival analysis of KEYNOTE-006
会议
Genomic analysis and 3-y efficacy and safety update of COMBI-d:A phase 3 study of dabrafenib(D)+tram
会议
A phase Ⅰb dose escalation trial of isatuximab(SAR650984,anti-CD38 mAb)plus lenalidomide and dexamet
会议
Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participantsin SWOG clini
会议
Benefits of physician orders for scope of treatment(POST)forms on end-of-life care incancer patients
会议
A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemothe
会议
Placebo-controlled phase Ⅲ study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor an
会议